Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2012-03-20
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT01126450
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
- Conditions
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2022-01-21
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 15
- Registration Number
- NCT01125176
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
- Conditions
- Interventions
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2015-12-03
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 21
- Registration Number
- NCT01123356
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Greenville Hospital System, Greenville, South Carolina, United States
Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP
- Conditions
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2021-07-26
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 650
- Registration Number
- NCT01122472
- Locations
- 🇵🇱
Oddzial Chorob Rozrostowych Regionalny Osrodek Onkologiczny, Lodz, Poland
🇧🇪ZNA Middelheim, Antwerpen, Belgium
🇧🇪Hopital Saint Joseph, Arlon, Belgium
Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-05-12
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 11
- Registration Number
- NCT01121757
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaCutaneous B-cell Non-Hodgkin LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueHepatosplenic T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPeripheral T-Cell LymphomaPost-transplant Lymphoproliferative Disorder
- Interventions
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01116154
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- ARCAGY/ GINECO GROUP
- Target Recruit Count
- 67
- Registration Number
- NCT01111903
- Locations
- 🇫🇷
Hopital Tenon, Paris, France
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
- Conditions
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2021-12-09
- Target Recruit Count
- 758
- Registration Number
- NCT01109004
- Locations
- 🇺🇸
Georgia Health Sciences University, Augusta, Georgia, United States
🇺🇸University of Kentucky, Lexington, Kentucky, United States
🇺🇸UCSD Medical Center, La Jolla, California, United States
Lenalidomide Maintenance Post-debulking in Advanced CTCL
- First Posted Date
- 2010-04-05
- Last Posted Date
- 2018-07-09
- Target Recruit Count
- 21
- Registration Number
- NCT01098656
- Locations
- 🇦🇹
Medical University of Graz, Graz, Austria
🇫🇷Nouvel Hopital Estaing, Clermont-Ferrand, Cedex 1, France
🇫🇷Chu de Bordeaux - Hopital Du Haut Leveque, Bordeaux, Pessac Cedex, France
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 25
- Registration Number
- NCT01093183
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.